The benefits and risks of alemtuzumab in multiple sclerosis

Author: Ontaneda Daniel   Cohen Jeffrey A  

Publisher: Informa Healthcare

ISSN: 1744-666X

Source: Expert Review of Clinical Immunology, Vol.9, Iss.3, 2013-03, pp. : 189-191

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract